公开(公告)号：US20240343829A1

公开(公告)日：2024-10-17

申请号：US18615934

申请日：2024-03-25

Applicant: Astria Therapeutics, Inc.

Inventor： Jou-Ku Chung ,  Christopher John Morabito ,  Andrew John Nichols

IPC: C07K16/40 ,  A61K9/00 ,  A61K39/00 ,  A61P43/00

CPC classification number: C07K16/40 ,  A61K9/0019 ,  A61P43/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/76

Abstract: The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).

公开(公告)号：US12102620B2

公开(公告)日：2024-10-01

申请号：US16943871

申请日：2020-07-30

Applicant: Deciphera Pharmaceuticals, LLC

Inventor： Daniel L. Flynn ,  Bryan D. Smith ,  Anu Gupta

IPC: A61K31/4375 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P43/00

CPC classification number: A61K31/4375 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P43/00

Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.

公开(公告)号：US20240316000A1

公开(公告)日：2024-09-26

申请号：US18575201

申请日：2022-06-29

Applicant: DIFFUSION PHARMACEUTICALS LLC

Inventor： Robert J. COBUZZI ,  Christopher D. GALLOWAY

IPC: A61K31/202 ,  A61P43/00

CPC classification number: A61K31/202 ,  A61P43/00

Abstract: Provided are novel methods of treatment of conditions such as peripheral tissue oxygenation, interstitial lung disease, dyspnea, ischemia from surgery, brain and pancreatic cancer with increased oxygen diffusivity comprising administering a diffusion enhancing compound, for example, trans sodium crocetinate.

公开(公告)号：US12098154B2

公开(公告)日：2024-09-24

申请号：US17715874

申请日：2022-04-07

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Nathanael S. Gray ,  Tinghu Zhang ,  Nicholas Paul Kwiatkowski

IPC: C07D487/04 ,  A61K45/06 ,  A61P43/00 ,  C07D473/16 ,  C07D473/34 ,  C07K14/47

CPC classification number: C07D473/16 ,  A61K45/06 ,  A61P43/00 ,  C07D473/34 ,  C07D487/04 ,  C07K14/4738

Abstract: The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

公开(公告)号：US12097180B2

公开(公告)日：2024-09-24

申请号：US17027057

申请日：2020-09-21

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： John J. McGlone

IPC: A61K31/404 ,  A61K9/00 ,  A61K31/20 ,  A61P25/00 ,  A61P43/00

CPC classification number: A61K31/404 ,  A61K9/0056 ,  A61K31/20 ,  A61P25/00 ,  A61P43/00

Abstract: Provided herein are maternal neonatal pheromonal agents capable of reducing aggression and improving feeding behavior in a pig. Compositions comprising the pheromonal agents and methods of using the agents to reduce aggression and improve feeding behavior and weight gain in the pig are also provided.

公开(公告)号：US20240299457A1

公开(公告)日：2024-09-12

申请号：US18484333

申请日：2023-10-10

Applicant: Steadman Philippon Research Institute

Inventor： Johnny HUARD ,  Marc Joseph PHILIPPON ,  Sudheer Kumar RAVURI ,  William Sealy HAMBRIGHT ,  Charles HUARD ,  Michael Terrance MULLEN, II ,  John Weston MITCHELL ,  Kaitlyn Elizabeth WHITNEY

IPC: A61K35/28 ,  A61K31/353 ,  A61K31/366 ,  A61P19/02 ,  A61P43/00 ,  G01N21/64 ,  G01N33/50 ,  G01N33/52

CPC classification number: A61K35/28 ,  A61K31/353 ,  A61K31/366 ,  A61P19/02 ,  A61P43/00 ,  G01N21/6428 ,  G01N33/5073 ,  G01N33/5091 ,  G01N33/52 ,  G01N2021/6439 ,  G01N2333/938 ,  G01N2458/30

Abstract: The present disclosure provides method of detecting senescent cells in a cell sample and methods of treating a disease, disorder, or condition associated with senescence in a subject by administering at least one senolytic agent to the subject.

公开(公告)号：US20240277911A1

公开(公告)日：2024-08-22

申请号：US18653906

申请日：2024-05-02

Applicant: Lyfspn, Inc.

Inventor： Dobri Kiprov

IPC: A61M1/34 ,  A61K35/17 ,  A61M1/36 ,  A61M1/38 ,  A61P43/00 ,  G01N33/569

CPC classification number: A61M1/3496 ,  A61K35/17 ,  A61P43/00 ,  G01N33/56972 ,  A61M1/342 ,  A61M1/361 ,  A61M1/3612 ,  A61M1/362 ,  A61M1/3693 ,  A61M1/38

Abstract: Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

公开(公告)号：US12064485B2

公开(公告)日：2024-08-20

申请号：US17363333

申请日：2021-06-30

Applicant: Amicus Therapeutics, Inc.

Inventor： Hung Do ,  Ce Feng Liu

IPC: C12N15/79 ,  A61K38/46 ,  A61K38/47 ,  A61K48/00 ,  A61P43/00 ,  C07H21/04 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A61K38/465 ,  A61K38/47 ,  A61K48/0033 ,  A61P43/00 ,  C12N15/86 ,  C07H21/04 ,  C12N15/79 ,  C12N2750/14143 ,  C12N2800/00 ,  C12Y301/02022 ,  C12Y302/01022

Abstract: Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy.

公开(公告)号：US20240238310A1

公开(公告)日：2024-07-18

申请号：US18434367

申请日：2024-02-06

Applicant: Northwestern University

Inventor： Serdar E. Bulun ,  Hong Zhao

IPC: A61K31/5685 ,  A61F2/00 ,  A61K9/00 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/566 ,  A61P43/00

CPC classification number: A61K31/5685 ,  A61F2/0063 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/566 ,  A61P43/00 ,  A61F2250/0067

Abstract: Disclosed are methods and compositions for treating and/or preventing hernias in subjects in need thereof. The disclosed methods of treatment and/or preventing may include methods for treating and/or preventing hernias in subject in need thereof by administering to the subject a therapeutic agent that modulates sex steroid hormone production and/or activity in the subject. Hernias treated and/or prevented by the disclosed methods may include, but are not limited to, inguinal hernias, femoral hernias, umbilical hernias, hiatal hernias, incisional hernias, and diastasis recti.

公开(公告)号：US12029800B2

公开(公告)日：2024-07-09

申请号：US16886001

申请日：2020-05-28

Applicant: POLA CHEMICAL INDUSTRIES, INC.

Inventor： Ryota Hayashi

IPC: A61K8/02 ,  A61K8/64 ,  A61K8/65 ,  A61K8/73 ,  A61K8/81 ,  A61K8/88 ,  A61K9/10 ,  A61K31/728 ,  A61K38/02 ,  A61P17/00 ,  A61P43/00 ,  A61Q19/00

CPC classification number: A61K8/0241 ,  A61K8/64 ,  A61K8/65 ,  A61K8/73 ,  A61K8/735 ,  A61K8/81 ,  A61K8/88 ,  A61K9/10 ,  A61K31/728 ,  A61K38/02 ,  A61P17/00 ,  A61P43/00 ,  A61Q19/00

Abstract: A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide.
Means for solving the first problem is a composite particle containing an anionic polymer, and a cationic polymer (except for chitosan) having a degree of cationization of 0.2 or more. Means for solving the second problem is to mix an anionic polymer and a peptide in an aqueous solvent having a pH of 5 or less.